Researchers led by University of Huddersfield scientist Dr Olumayokun Olajide are currently conducting a new study through which they hope to develop a new drug for stopping the development of dementia and Alzheimer's by making use of an ingredient found in pomegranate that has already been found to slow down and curb some of the symptoms of the neurological disease.
The key breakthrough by Dr Olajide and his co-researchers is to demonstrate that punicalagin, which is a polyphenol - a form of chemical compound - found in pomegranate fruit, can inhibit inflammation in specialised brain cells known as micrologia. This inflammation leads to the destruction of more and more brain cells, making the condition of Alzheimer's sufferers progressively worse.
AdvertisementThere is still no cure for the disease, but the punicalagin in pomegranate could prevent it or slow down its development.
Dr Olajide worked with co-researchers - including four PhD students - in the University of Huddersfield's Department of Pharmacy and with scientists at the University of Freiburg in Germany. The team used brain cells isolated from rats in order to test their findings. Now the research is published in the latest edition of the journal Molecular Nutrition & Food Research and Dr Olajide will start to disseminate his findings at academic conferences.
He is still working on the amounts of pomegranate that are required, in order to be effective.
"But we do know that regular intake and regular consumption of pomegranate has a lot of health benefits - including prevention of neuro-inflammation related to dementia," he says, recommending juice products that are 100 percent pomegranate, meaning that approximately 3.4 percent will be punicalagin, the compound that slows down the progression of dementia.
Dr Olajide states that most of the anti-oxidant compounds are found in the outer skin of the pomegranate, not in the soft part of the fruit. And he adds that although this has yet to be scientifically evaluated, pomegranate will be useful in any condition for which inflammation - not just neuro-inflammation - is a factor, such as rheumatoid arthritis, Parkinson's and cancer.
The research continues and now Dr Olajide is collaborating with his University of Huddersfield colleague, the organic chemist Dr Karl Hemming. They will attempt to produce compound derivatives of punicalagin that could the basis of new, orally administered drugs that would treat neuro-inflammation.
Dr Olajide has been a Senior Lecturer at the University of Huddersfield for four years. His academic career includes a post as a Humboldt Postdoctoral Research Fellow at the Centre for Drug Research at the University of Munich. His PhD was awarded from the University of Ibadan in his native Nigeria, after an investigation of the anti-inflammatory properties of natural products.
He attributes this area of research to his upbringing. "African mothers normally treat sick children with natural substances such as herbs. My mum certainly used a lot of those substances. And then I went on to study pharmacology!"